SCHEMBL26295692

SCHEMBL26295692

CC(C)C1CCN(C(=O)C2CCN(CCCC3CCN(C(C)C)CC3)CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 4/20 0.40
USP2 O75604 1/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 1/20 0.38
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26295685 0.93 HRH3 (0.43) HRH3HPGDPOLBPKMALDH1A1
SCHEMBL26494241 0.91 HRH3 (0.41) HRH3HPGDPOLBPKMALDH1A1
SCHEMBL26494246 0.90 POLB (0.48) HPGDPOLBPKMALDH1A1USP2
SCHEMBL26295701 0.90 HRH3 (0.48) HRH3HPGDPOLBPKMALDH1A1
SCHEMBL25075431 0.88 HRH3 (0.48) HRH3ALDH1A1USP2SIGMAR1BLM
SCHEMBL26494244 0.86 HPGD (0.46) HRH3HPGDPOLBPKMMEN1
SCHEMBL26494067 0.86 GNAO1 (0.41) HRH3DRD2DRD3CHRM2CHRM4
SCHEMBL26295658 0.85 HRH3 (0.47) HRH3DRD2DRD3CHRM2CHRM4
SCHEMBL25074969 0.85 SMN1; SMN2 (0.52) HRH3ALDH1A1SIGMAR1SMN1; SMN2HSD11B1
SCHEMBL26295683 0.85 HRH3 (0.50) HRH3ALDH1A1USP2SIGMAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES ENDOTARGET INC. 2023-09-21 US disclosed
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES ENDOTARGET INC. 2023-09-21 US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES CDK6, CDK4, CDK1 HRH3 2877/4885HPGD 2101/4885POLB 801/4885
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN HRH3 3222/4885HPGD 4528/4885POLB 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.